Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ANPEP | P15144 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3691998 | 1.00 | TGM2 (0.45) | TGM2CA1CA2FOLH1HTT | |
| SCHEMBL7642842 | 0.96 | CPB1 (0.47) | TGM2CA1CA2FOLH1MAPT | |
| SCHEMBL3700787 | 0.92 | L3MBTL1 (0.47) | CA1CA2HTTMAPTL3MBTL1 | |
| SCHEMBL3689532 | 0.86 | MTNR1B (0.43) | L3MBTL1SMN1; SMN2 | |
| SCHEMBL3693466 | 0.84 | HTT (0.43) | TGM2CA1CA2FOLH1HTT | |
| SCHEMBL4421178 | 0.82 | HDAC6 (0.47) | SMN1; SMN2 | |
| SCHEMBL14315813 | 0.81 | ALDH1A1 (0.50) | SMN1; SMN2 | |
| SCHEMBL29450730 | 0.81 | LMNA (0.62) | CA1CA2HTTMAPTL3MBTL1 | |
| SCHEMBL26634636 | 0.81 | TGM2 (0.60) | TGM2FOLH1HTTMAPTL3MBTL1 | |
| SCHEMBL524569 | 0.79 | SLC6A11 (0.47) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081949-B1 | TRIPARTITE OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE | GE HEALTHCARE DHARMACON INC (US) | 2014-12-10 | — | — | EP | disclosed |
| US-8809514-B2 | Tripartite oligonucleotide complexes and methods for gene silencing by RNA interference | GE HEALTHCARE DHARMACON, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8501706-B2 | Duplex oligonucleotide complexes and methods for gene silencing by RNA interference | DHARMACON, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| EP-2064223-B1 | Duplex oligonucleotide complexes and methods for gene silencing by RNA interference | DHARMACON INC (US) | 2013-04-24 | — | — | EP | disclosed |
| US-20120322855-A1 | Duplex Oligonucleotide Complexes and Methods for Gene Silencing by RNA Interference | DHARMACON, INC. (US) | 2012-12-20 | — | — | US | disclosed |
| US-8252755-B2 | Duplex oligonucleotide complexes and methods for gene silencing by RNA interference | DHARMACON, INC. (US) | 2012-08-28 | — | — | US | disclosed |
| US-20100093085-A1 | TRIPARTITE OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE | DHARMACON, INC (US) | 2010-04-15 | — | — | US | disclosed |
| EP-2081949-A2 | TRIPARTITE OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE | Dharmacon, Inc. (US) | 2009-07-29 | — | — | EP | disclosed |
| EP-2064223-A2 | DUPLEX OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE | Dharmacon, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20080085869-A1 | Sense strand, antisense strand having complementarity to both the sense strand and a target gene, forming a duplex, a conjugate, facilitating cellular delivery, and a linker molecule; facilitates delivery to a cell, tissue or organism | DHARMACON, INC. (US) | 2008-04-10 | — | — | US | disclosed |
| WO-2008036825-A2 | DUPLEX OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE | DHARMACON, INC. (US) | 2008-03-27 | — | — | WO | disclosed |
| WO-2008036841-A2 | TRIPARTITE OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE | DHARMACON, INC. (US) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093085-A1 | TRIPARTITE OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE | SNRPE, DCLRE1B, RNASE1 | TGM2 2500/4885CA1 4194/4885CA2 4779/4885 |
| US-20120322855-A1 | Duplex Oligonucleotide Complexes and Methods for Gene Silencing by RNA Interference | SNRPE, AGO2, DCLRE1B | TGM2 2530/4885CA1 4593/4885CA2 4719/4885 |
| US-20080085869-A1 | Sense strand, antisense strand having complementarity to both the sense strand and a target gene, forming a duplex, a conjugate, facilitating cellular delivery, and a linker molecule; facilitates delivery to a cell, tissue or organism | SRRT, SNRPE, SSBP1 | TGM2 1258/4885CA1 3479/4885CA2 3978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.